Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy (Review)
- Authors:
- Yumeng Wei
- Xinlin Pu
- Ling Zhao
-
Affiliations: Department of Pharmaceutics, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646099, P.R. China, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646099, P.R. China - Published online on: April 20, 2017 https://doi.org/10.3892/or.2017.5593
- Pages: 3159-3166
This article is mentioned in:
Abstract
 |
 |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Szekeres T and Novotny L: New targets and drugs in cancer chemotherapy. Med Princ Pract. 11:117–125. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, Levinson KL, Tanner EJ III, Stone RL, Piotrowski A, et al: Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol. 140:76–82. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sideris S, Aoun F, Zanaty M, Martinez NC, Latifyan S, Awada A and Gil T: Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol. 4:1063–1067. 2016.PubMed/NCBI | |
|
Dilruba S and Kalayda GV: Platinum-based drugs: Past, present and future. Cancer Chemother Pharmacol. 77:1103–1124. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Pan X, Zhang X, Sun H, Zhang J, Yan M and Zhang H: Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One. 8:e566792013. View Article : Google Scholar : PubMed/NCBI | |
|
Emadi A, Jones RJ and Brodsky RA: Cyclophosphamide and cancer: Golden anniversary. Nat Rev Clin Oncol. 6:638–647. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S and Rustum YM: Irinotecan in the treatment of colorectal cancer: Clinical overview. J Clin Oncol. 19:1501–1518. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Xu T, Qin L, Zhu Z, Wang X, Liu Y, Fan Y, Zhong S, Wang X, Zhang X, Xia L, et al: MicroRNA-31 functions as a tumor suppressor and increases sensitivity to mitomycin-C in urothelial bladder cancer by targeting integrin α5. Oncotarget. 7:27445–27457. 2016.PubMed/NCBI | |
|
Bae YJ, Yoon YI, Yoon TJ and Lee HJ: Ultrasound-guided delivery of siRNA and a chemotherapeutic drug by using microbubble complexes: In vitro and in vivo evaluations in a prostate cancer model. Korean J Radiol. 17:497–508. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou Q, Ye M, Lu Y, Zhang H, Chen Q, Huang S and Su S: Curcumin improves the tumoricidal effect of mitomycin C by suppressing ABCG2 expression in stem cell-like breast cancer cells. PLoS One. 10:e01366942015. View Article : Google Scholar : PubMed/NCBI | |
|
Wei Z, Liang L, Junsong L, Rui C, Shuai C, Guanglin Q, Shicai H, Zexing W, Jin W, Xiangming C, et al: The impact of insulin on chemotherapeutic sensitivity to 5-fluorouracil in gastric cancer cell lines SGC7901, MKN45 and MKN28. J Exp Clin Cancer Res. 34:642015. View Article : Google Scholar : PubMed/NCBI | |
|
Talekar M, Ouyang Q, Goldberg MS and Amiji MM: Cosilencing of PKM-2 and MDR-1 sensitizes multidrug-resistant ovarian cancer cells to paclitaxel in a murine model of ovarian cancer. Mol Cancer Ther. 14:1521–1531. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Kenicer J, Spears M, Lyttle N, Taylor KJ, Liao L, Cunningham CA, Lambros M, MacKay A, Yao C, Reis-Filho J, et al: Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance. BMC Cancer. 14:762–772. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Martín AJ, Alfonso PG, Rupérez AB and Jiménez MM: Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncol Lett. 12:727–730. 2016.PubMed/NCBI | |
|
Ebara S, Kobayashi Y, Sasaki K, Araki M, Sugimoto M, Wada K, Fujio K, Takamoto A, Watanabe T, Yanai H, et al: A case of metastatic urachal cancer including a neuroendocrine component treated with gemcitabine, cisplatin and paclitaxel combination chemotherapy. Acta Med Okayama. 70:223–227. 2016.PubMed/NCBI | |
|
Kalaghchi B, Abdi R, Amouzegar-Hashemi F, Esmati E and Alikhasi A: Concurrent chemoradiation with weekly paclitaxel and cisplatin for locally advanced cervical cancer. Asian Pac J Cancer Prev. 17:287–291. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Yilmaz A, Alp E, Onen HI and Menevse S: Reduced BCL2 and CCND1 mRNA expression in human cervical cancer HeLa cells treated with a combination of everolimus and paclitaxel. Contemp Oncol (Pozn). 20:28–32. 2016.PubMed/NCBI | |
|
Trendowski M, Christen TD, Acquafondata C and Fondy TP: Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro. BMC Cancer. 15:632–645. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
van der Noll R, Marchetti S, Steeghs N, Beijnen JH, Mergui-Roelvink MW, Harms E, Rehorst H, Sonke GS and Schellens JH: Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer. Br J Cancer. 113:396–402. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Huang L, Chen S, Yang W, Xu B, Huang T, Yang H, Zheng H, Wang Y, Song E, Zhang J, et al: Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II–III, HER2-positive breast cancer patients: A phase 2, open-label, multicenter, randomized trial. Oncotarget. 6:18683–18692. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao B, Si X, Han MK, Viennois E, Zhang M and Merlin D: Co-delivery of camptothecin and curcumin by cationic polymeric nanoparticles for synergistic colon cancer combination chemotherapy. J Mater Chem B Mater Biol Med. 3:7724–7733. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Tsuda N, Watari H and Ushijima K: Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chin J Cancer Res. 28:241–253. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Schwab CL, English DP, Roque DM and Santin AD: Taxanes: Their impact on gynecologic malignancy. Anticancer Drugs. 25:522–535. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wani MC and Horwitz SB: Nature as a remarkable chemist: A personal story of the discovery and development of Taxol. Anticancer Drugs. 25:482–487. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Weaver BA: How Taxol/paclitaxel kills cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang D, Yang R, Wang S and Dong Z: Paclitaxel: New uses for an old drug. Drug Des Devel Ther. 8:279–284. 2014.PubMed/NCBI | |
|
Takashima S, Kiyoto S, Takahashi M, Hara F, Aogi K, Ohsumi S, Mukai R and Fujita Y: Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer. Oncol Lett. 9:1822–1826. 2015.PubMed/NCBI | |
|
Chen NC, Chyau CC, Lee YJ, Tseng HC and Chou FP: Promotion of mitotic catastrophe via activation of PTEN by paclitaxel with supplement of mulberry water extract in bladder cancer cells. Sci Rep. 6:204172016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong ZF, Tan W, Wang SP, Qiang WA and Wang YT: Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. Sci Rep. 5:164152015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu K, Cang S, Ma Y and Chiao JW: Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell Int. 13:102013. View Article : Google Scholar : PubMed/NCBI | |
|
Takatori E, Shoji T, Kumagai S, Sawai T, Kurose A and Sugiyama T: Are platinum agents, paclitaxel and irinotecan effective for clear cell carcinoma of the ovary? DNA damage detected with γH2AX induced by anticancer agents. J Ovarian Res. 5:162012. View Article : Google Scholar : PubMed/NCBI | |
|
Harisa GI, Ibrahim MF, Alanazi F and Shazly GA: Engineering erythrocytes as a novel carrier for the targeted delivery of the anticancer drug paclitaxel. Saudi Pharm J. 22:223–230. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wu ZH, Lu MK, Hu LY and Li X: Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One. 7:e517212012. View Article : Google Scholar : PubMed/NCBI | |
|
Li CM, Lu Y, Chen J, Costello TA, Narayanan R, Dalton MN, Snyder LM, Ahn S, Li W, Miller DD, et al: Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Pharm Res. 29:3053–3063. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Oostendorp RL, Buckle T, Lambert G, Garrigue JS, Beijnen JH, Schellens JH and van Tellingen O: Paclitaxel in self-micro emulsifying formulations: Oral bioavailability study in mice. Invest New Drugs. 29:768–776. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Borst P and Schinkel AH: P-glycoprotein ABCB1: A major player in drug handling by mammals. J Clin Invest. 123:4131–4133. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Sui H, Fan ZZ and Li Q: Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells. J Int Med Res. 40:426–435. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim H, Park GS, Lee JE and Kim JH: A leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cells. Br J Cancer. 109:351–359. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ran X, Yang J, Liu C, Zhou P, Xiao L and Zhang K: MiR-218 inhibits HMGB1-mediated autophagy in endometrial carcinoma cells during chemotherapy. Int J Clin Exp Pathol. 8:6617–6626. 2015.PubMed/NCBI | |
|
Yang X, Iyer AK, Singh A, Choy E, Hornicek FJ, Amiji MM and Duan Z: MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep. 5:85092015. View Article : Google Scholar : PubMed/NCBI | |
|
Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, Amiji MM and Duan Z: Cluster of differentiation 44 targeted hyaluronic acid based nanoparticles for MDR1 siRNA delivery to overcome drug resistance in ovarian cancer. Pharm Res. 32:2097–2109. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mao K, Liu F, Liu X, Khuri FR, Marcus AI, Li M and Zhou W: Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression. Lung Cancer. 88:131–138. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP, Sun JY, Wang TT, Xie J, He HR, Xing JF, et al: Establishment of paclitaxel-resistant breast cancer cell line and nude mice models, and underlying multidrug resistance mechanisms in vitro and in vivo. Asian Pac J Cancer Prev. 14:6135–6140. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M and Zabel M: MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. BioMed Res Int. 2013:2417632013. View Article : Google Scholar : PubMed/NCBI | |
|
Wu G, Qin XQ, Guo JJ, Li TY and Chen JH: AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 7:1449–1458. 2014.PubMed/NCBI | |
|
Jeong JY, Kim KS, Moon JS, Song JA, Choi SH, Kim KI, Kim TH and An HJ: Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Apoptosis. 18:509–520. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Zhu G, Getzenberg RH and Veltri RW: The upregulation of PI3K/Akt and MAP kinase pathways is associated with resistance of microtubule-targeting drugs in prostate cancer. J Cell Biochem. 116:1341–1349. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Mei M, Xie D, Zhang Y, Jin J, You F, Li Y, Dai J and Chen X: A new 2α,5α,10β,14β-tetraacetoxy-4(20),11-taxadiene (SIA) derivative overcomes paclitaxel resistance by inhibiting MAPK signaling and increasing paclitaxel accumulation in breast cancer cells. PLoS One. 9:e1043172014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou M, Fan C and Tian N: Effects of curcumin on the gene expression profile of L-02 cells. Biomed Rep. 3:519–526. 2015.PubMed/NCBI | |
|
Zhang Y, Liang D, Dong L, Ge X, Xu F, Chen W, Dai Y, Li H, Zou P, Yang S, et al: Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury. Respir Res. 16:432015. View Article : Google Scholar : PubMed/NCBI | |
|
Fan Z, Yao J, Li Y, Hu X, Shao H and Tian X: Anti-inflammatory and antioxidant effects of curcumin on acute lung injury in a rodent model of intestinal ischemia reperfusion by inhibiting the pathway of NF-κB. Int J Clin Exp Pathol. 8:3451–3459. 2015.PubMed/NCBI | |
|
Ferreira VH, Nazli A, Dizzell SE, Mueller K and Kaushic C: The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. PLoS One. 10:e01249032015. View Article : Google Scholar : PubMed/NCBI | |
|
Robles-Escajeda E, Das U, Ortega NM, Parra K, Francia G, Dimmock JR, Varela-Ramirez A and Aguilera RJ: A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol (Dordr). 39:265–277. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Park W, Amin AR, Chen ZG and Shin DM: New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 6:387–400. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou H, Beevers CS and Huang S: The targets of curcumin. Curr Drug Targets. 12:332–347. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Philip M, Rowley DA and Schreiber H: Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol. 14:433–439. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Cao F, Liu T, Xu Y, Xu D and Feng S: Curcumin inhibits cell proliferation and promotes apoptosis in human osteoclastoma cell through MMP-9, NF-κB and JNK signaling pathways. Int J Clin Exp Pathol. 8:6037–6045. 2015.PubMed/NCBI | |
|
Bansal SS, Goel M, Aqil F, Vadhanam MV and Gupta RC: Advanced drug delivery systems of curcumin for cancer chemoprevention. Cancer Prev Res (Phila). 4:1158–1171. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Guan F, Ding Y, Zhang Y, Zhou Y, Li M and Wang C: Curcumin suppresses proliferation and migration of MDA-MB-231 breast cancer cells through autophagy-dependent Akt degradation. PLoS One. 11:e01465532016. View Article : Google Scholar : PubMed/NCBI | |
|
Collett GP and Campbell FC: Curcumin induces c-jun N-terminal kinase-dependent apoptosis in HCT116 human colon cancer cells. Carcinogenesis. 25:2183–2189. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Lu Y, Jin Y, Son JK, Lee SH and Chang HW: Curcumin inhibits the activation of immunoglobulin e-mediated mast cells and passive systemic anaphylaxis in mice by reducing serum eicosanoid and histamine levels. Biomol Ther (Seoul). 22:27–34. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D and Chen Z: The effect of curcumin on breast cancer cells. J Breast Cancer. 16:133–137. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Astuti PD, Utami E, Nugrahani AW and Sudjadi S: Genistein abrogates G2 arrest induced by curcumin in p53 deficient T47D cells. Daru. 20:822012. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng C, Jiao JT, Qian Y, Guo XY, Huang J, Dai MC, Zhang L, Ding XP, Zong D and Shao JF: Curcumin induces G2/M arrest and triggers apoptosis via FoxO1 signaling in U87 human glioma cells. Mol Med Rep. 13:3763–3770. 2016.PubMed/NCBI | |
|
Eom DW, Lee JH, Kim YJ, Hwang GS, Kim SN, Kwak JH, Cheon GJ, Kim KH, Jang HJ, Ham J, et al: Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells. BMB Rep. 48:461–466. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao J, Chu Y, Hu K, Wan J, Huang Y, Jiang C, Liang G and Li X: Synthesis and biological analysis of a new curcumin analogue for enhanced anti-tumor activity in HepG 2 cells. Oncol Rep. 23:1435–1441. 2010.PubMed/NCBI | |
|
Zhang Y, Jiang X, Peng K, Chen C, Fu L, Wang Z, Feng J, Liu Z, Zhang H, Liang G, et al: Discovery and evaluation of novel anti-inflammatory derivatives of natural bioactive curcumin. Drug Des Devel Ther. 8:2161–2171. 2014.PubMed/NCBI | |
|
Zhang Y, Zhao C, He W, Wang Z, Fang Q, Xiao B, Liu Z, Liang G and Yang S: Discovery and evaluation of asymmetrical monocarbonyl analogs of curcumin as anti-inflammatory agents. Drug Des Devel Ther. 8:373–382. 2014.PubMed/NCBI | |
|
Olivera A, Moore TW, Hu F, Brown AP, Sun A, Liotta DC, Snyder JP, Yoon Y, Shim H, Marcus AI, et al: Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): Anti-inflammatory and anti-cancer properties. Int Immunopharmacol. 12:368–377. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Balanda M, Quiero A, Vergara N, Espinoza G, Martín HS, Rojas G and Ramírez E: Prevalence of human papillomavirus infection among women presenting for cervical cancer screening in Chile, 2014–2015. Med Microbiol Immunol (Berl). 205:585–594. 2016. View Article : Google Scholar | |
|
Bava SV, Puliappadamba VT, Deepti A, Nair A, Karunagaran D and Anto RJ: Sensitization of taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. J Biol Chem. 280:6301–6308. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Bava SV, Sreekanth CN, Thulasidasan AKT, Anto NP, Cheriyan VT, Puliyappadamba VT, Menon SG, Ravichandran SD and Anto RJ: Akt is upstream and MAPKs are downstream of NF-κB in paclitaxel-induced survival signaling events, which are down-regulated by curcumin contributing to their synergism. Int J Biochem Cell Biol. 43:331–341. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Sreekanth CN, Bava SV, Sreekumar E and Anto RJ: Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene. 30:3139–3152. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Dang YP, Yuan XY, Tian R, Li DG and Liu W: Curcumin improves the paclitaxel-induced apoptosis of HPV-positive human cervical cancer cells via the NF-κB-p53-caspase-3 pathway. Exp Ther Med. 9:1470–1476. 2015.PubMed/NCBI | |
|
Punfa W, Suzuki S, Pitchakarn P, Yodkeeree S, Naiki T, Takahashi S and Limtrakul P: Curcumin-loaded PLGA nanoparticles conjugated with anti-P-glycoprotein antibody to overcome multidrug resistance. Asian Pac J Cancer Prev. 15:9249–9258. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Faião-Flores F, Suarez JAQ, Pardi PC and Maria DA: DM-1, sodium 4-(5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl)-2-methoxy-phenolate: A curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment. Tumour Biol. 33:775–785. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee M, Singh P and Panda D: Curcumin suppresses the dynamic instability of microtubules, activates the mitotic checkpoint and induces apoptosis in MCF-7 cells. FEBS J. 277:3437–3448. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhan Y, Chen Y, Liu R, Zhang H and Zhang Y: Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling. Arch Pharm Res. 37:1086–1095. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Boztas AO, Karakuzu O, Galante G, Ugur Z, Kocabas F, Altuntas CZ and Yazaydin AO: Synergistic interaction of paclitaxel and curcumin with cyclodextrin polymer complexation in human cancer cells. Mol Pharm. 10:2676–2683. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Thadakapally R, Aafreen A, Aukunuru J, Habibuddin M and Jogala S: Preparation and characterization of PEG-albumin-curcumin nanoparticles intended to treat breast cancer. Indian J Pharm Sci. 78:65–72. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Royt M, Mukherjee S, Sarkar R and Biswas J: Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-kappaB and HDAC in breast cancer. Ther Deliv. 2:1275–1293. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Kang HJ, Lee SH, Price JE and Kim LS: Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J. 15:223–229. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Wang F, Li F, Zhang W, Shen Y, Zhou D and Guo S: A multifunctional poly(curcumin) nanomedicine for dual-modal targeted delivery, intracellular responsive release, dual-drug treatment and imaging of multidrug resistant cancer cells. J Mater Chem B Mater Biol Med. 4:2954–2962. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ganta S, Devalapally H and Amiji M: Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci. 99:4630–4641. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Innamaa A, Jackson L, Asher V, van Schalkwyk G, Warren A, Keightley A, Hay D, Bali A, Sowter H and Khan R: Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer. Clin Transl Oncol. 15:910–918. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Deng S, Xu J, Li R and Zhou Q: Inhibitory effect of curcumin-loaded solid lipid nanoparticles combined with paclitaxel on human ovarian cancer cell line HO-8910. China Pharmacy. 24:1756–1759. 2013.http://en.cnki.com.cn/Article_en/CJFDTOTAL-ZGYA201319013.htm | |
|
Abouzeid AH, Patel NR, Sarisozen C and Torchilin VP: Transferrin-targeted polymeric micelles co-loaded with curcumin and paclitaxel: Efficient killing of paclitaxel-resistant cancer cells. Pharm Res. 31:1938–1945. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Zhu YY, Li ZY and Ning SQ: Evaluation of the efficacy of paclitaxel with curcumin combination in ovarian cancer cells. Oncol Lett. 12:3944–3948. 2016.PubMed/NCBI | |
|
Kar R, Sharma C, Sen S, Jain SK, Gupta SD and Singh N: Response of primary culture of human ovarian cancer cells to chemotherapy: In vitro individualized therapy. J Cancer Res Ther. 12:1050–1055. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Galia A, Calogero AE, Condorelli R, Fraggetta F, La Corte A, Ridolfo F, Bosco P, Castiglione R and Salemi M: PARP-1 protein expression in glioblastoma multiforme. Eur J Histochem. 56:e92012. View Article : Google Scholar : PubMed/NCBI | |
|
Hossain M, Banik NL and Ray SK: Synergistic anti-cancer mechanisms of curcumin and paclitaxel for growth inhibition of human brain tumor stem cells and LN18 and U138MG cells. Neurochem Int. 61:1102–1113. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Manju S, Sharma CP and Sreenivasan K: Targeted coadministration of sparingly soluble paclitaxel and curcumin into cancer cells by surface engineered magnetic nanoparticles. J Mater Chem. 21:15708–15717. 2011. View Article : Google Scholar | |
|
Cui Y, Zhang M, Zeng F, Jin H, Xu Q and Huang Y: Dual-targeting magnetic PLGA Nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Appl Mater Interfaces. 8:32159–32169. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kamat AM, Sethi G and Aggarwal BB: Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther. 6:1022–1030. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao H, Yu X, Qi R, Shang F and Su Z: Inhibitory effects of curcumin in combination with paclitaxel on prostate cancer xenografted model. Xiandai Shengwu Yixue Jinzhan. 10:823–827. 2010.(In Chinese). | |
|
Wand D, Qi R, Zhao H and Yu X: Effects of curcumin combined with paclitaxel on the invasion and senescence of human prostatic carcinoma PC3 cells. Xiandai Shengwu Yixue Jinzhan. 12:6239–6241. 2012.(In Chinese). | |
|
Huang YT, Huang DM, Chueh SC, Teng CM and Guh JH: Alisol B acetate, a triterpene from Alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells. Cancer Lett. 231:270–278. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas SL, Zhong D, Zhou W, Malik S, Liotta D, Snyder JP, Hamel E and Giannakakou P: EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle. 7:2409–2417. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mathur A, Abd Elmageed ZY, Liu X, Kostochka ML, Zhang H, Abdel-Mageed AB and Mondal D: Subverting ER-stress towards apoptosis by nelfinavir and curcumin coexposure augments docetaxel efficacy in castration resistant prostate cancer cells. PLoS One. 9:e1031092014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang JD and Roberts LR: Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wei KR, Yu X, Zheng RS, Peng XB, Zhang SW, Ji MF, Liang ZH, Ou ZX and Chen WQ: Incidence and mortality of liver cancer in China, 2010. Chin J Cancer. 33:388–394. 2014.PubMed/NCBI | |
|
Byam J, Renz J and Millis JM: Liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2:22–30. 2013.PubMed/NCBI | |
|
Zhou M, Li Z, Han Z and Tian N: Paclitaxel-sensitization enhanced by curcumin involves down-regulation of nuclear factor-κB and Lin28 in Hep3B cells. J Recept Signal Transduct Res. 35:618–625. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
O'Day E, Le MTN, Imai S, Tan SM, Kirchner R, Arthanari H, Hofmann O, Wagner G and Lieberman J: An RNA-binding protein, Lin28, recognizes and remodels g-quartets in the microRNAs (miRNAs) and mRNAs it regulates. J Biol Chem. 290:17909–17922. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dubey AK, Gupta U and Jain S: Epidemiology of lung cancer and approaches for its prediction: A systematic review and analysis. Chin J Cancer. 35:71–83. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Muthoosamy K, Abubakar IB, Bai RG, Loh HS and Manickam S: Exceedingly higher co-loading of curcumin and paclitaxel onto polymer-functionalized reduced graphene oxide for highly potent synergistic anticancer treatment. Sci Rep. 6:328082016. View Article : Google Scholar : PubMed/NCBI | |
|
Su GM, Davey MW and Davey RA: Induction of broad drug resistance in small cell lung cancer cells and its reversal by paclitaxel. Int J Cancer. 76:702–708. 1998. View Article : Google Scholar : PubMed/NCBI | |
|
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V and Kurzrock R: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 14:4491–4499. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Epelbaum R, Schaffer M, Vizel B, Badmaev V and Bar-Sela G: Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr Cancer. 62:1137–1141. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Irving GR, Iwuji CO, Morgan B, Berry DP, Steward WP, Thomas A, Brown K and Howells LM: Combining curcumin (C3-complex, Sabinsa) with standard care FOLFOX chemotherapy in patients with inoperable colorectal cancer (CUFOX): Study protocol for a randomised control trial. Trials. 16:1102015. View Article : Google Scholar : PubMed/NCBI | |
|
Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C and Chollet P: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther. 9:8–14. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert M, et al: The new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: A pilot phase II study. Oncology. 90:69–78. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kodama Y, Matsumoto S, et al: A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. 71:1521–1530. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Bolger G, Helson L and Wolzt M: Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther. 53:54–65. 2015. View Article : Google Scholar : PubMed/NCBI |
